Novo Nordisk announced that it will significantly reduce the U.S. list prices of its widely used weight-loss drugs Wegovy, Ozempic and Rybelsus, starting Jan. 1, 2027.
The company said all doses will shift to one monthly list price of $675, cutting the price of Wegovy by about half and Ozempic by roughly a third. Novo Nordisk explained that the change is meant to make the medications more affordable for people who pay based on the official list price, especially those with high‑deductible insurance plans.
The company said the price cut comes at a time when demand for these drugs is higher than ever.
Researchers who found that obesity dipped for the first time in more than a decade suggested that weight loss drugs like Ozempic might play a role.
Jamey Millar, executive vice president of U.S. operations, said the new pricing is meant to help millions of Americans dealing with obesity or type 2 diabetes who could benefit from these treatments.
“Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States. Private and public payers, as well as patients, want access and have been calling for lower list prices,” Millar said in a statement.
The company pointed out that this drug family is still the only one of its kind approved by the FDA for several major health conditions, including obesity, type 2 diabetes, certain kidney problems and heart‑related risks.
Novo Nordisk described the price cuts as part of a long‑term plan to make the medications easier to access and to respond to growing concerns about how expensive these drugs have become. The new pricing is expected to have a major impact on the market when it takes effect in 2027.
Leave a Reply